eFFECTOR Therapeutics, Inc.
DelistedCIK 1828522fmd_0MG761PS0H74SW48TR6KK9YPRVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Mar 31, 2024, 17 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Total revenues | 42 | 1 | 4 | 0 |
| Research and development | 22 | 20 | 23 | 23 |
| Total operating expenses | 26 | 33 | 36 | 34 |
| Operating income | 16 | (32) | (32) | (34) |
| Interest expense | 1 | 2 | 2 | 3 |
| Interest and investment income | 0 | 0 | 0 | 1 |
| Other non-operating income (expense) | (1) | 48 | 10 | (2) |
| Income before taxes | 15 | 16 | – | – |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 14 | 16 | (23) | – |
| Net income | 14 | 16 | (23) | (36) |
| Net income to common shareholders | 0 | 16 | (23) | – |